| Diana L Mancini, MD | |
|
4747 Arapahoe Ave, Boulder, CO 80303-1133 | |
| (303) 415-7610 | |
| (303) 415-7618 |
| Full Name | Diana L Mancini |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 21 Years |
| Location | 4747 Arapahoe Ave, Boulder, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619990090 | NPI | - | NPPES |
| 03457389 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 44925 (Colorado) | Secondary |
| 207R00000X | Internal Medicine | 44925 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Denver Health & Hospital Authority | Denver, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Denver Health And Hospital Authority | 4688583578 | 650 |
News Archive
Researchers at the University of North Carolina at Chapel Hill School of Medicine in collaboration with lead investigators at the University of Kentucky have identified a new target for the diagnosis and treatment of age-related macular degeneration, the most common cause of blindness in older Americans.
Protea Biosciences, Inc., a leading developer of new technology for pharmaceutical research, announced today that the company, in partnership with Mayoly-Spindler, a European pharmaceutical company, has commenced a Phase I/IIA human clinical trial for a new recombinant Lipase.
As healthcare reform is being debated in Congress and on Main Street, vital and practical issues in eldercare and family caregiving are being overlooked. Some 30 million U.S. baby boomers are family caregivers for their aging parents, trying to keep their parents safe at home and helping them navigate the complexities of Medicare and manage an advancing illness. If they had their say, most elderly people would prefer to age in their own homes.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
› Verified 6 days ago
| Entity Name | Denver Health And Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477569838 PECOS PAC ID: 4688583578 Enrollment ID: O20031105000211 |
News Archive
Researchers at the University of North Carolina at Chapel Hill School of Medicine in collaboration with lead investigators at the University of Kentucky have identified a new target for the diagnosis and treatment of age-related macular degeneration, the most common cause of blindness in older Americans.
Protea Biosciences, Inc., a leading developer of new technology for pharmaceutical research, announced today that the company, in partnership with Mayoly-Spindler, a European pharmaceutical company, has commenced a Phase I/IIA human clinical trial for a new recombinant Lipase.
As healthcare reform is being debated in Congress and on Main Street, vital and practical issues in eldercare and family caregiving are being overlooked. Some 30 million U.S. baby boomers are family caregivers for their aging parents, trying to keep their parents safe at home and helping them navigate the complexities of Medicare and manage an advancing illness. If they had their say, most elderly people would prefer to age in their own homes.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Diana L Mancini, MD 5450 Western Ave, Boulder, CO 80301-2709 Ph: (303) 415-7610 | Diana L Mancini, MD 4747 Arapahoe Ave, Boulder, CO 80303-1133 Ph: (303) 415-7610 |
News Archive
Researchers at the University of North Carolina at Chapel Hill School of Medicine in collaboration with lead investigators at the University of Kentucky have identified a new target for the diagnosis and treatment of age-related macular degeneration, the most common cause of blindness in older Americans.
Protea Biosciences, Inc., a leading developer of new technology for pharmaceutical research, announced today that the company, in partnership with Mayoly-Spindler, a European pharmaceutical company, has commenced a Phase I/IIA human clinical trial for a new recombinant Lipase.
As healthcare reform is being debated in Congress and on Main Street, vital and practical issues in eldercare and family caregiving are being overlooked. Some 30 million U.S. baby boomers are family caregivers for their aging parents, trying to keep their parents safe at home and helping them navigate the complexities of Medicare and manage an advancing illness. If they had their say, most elderly people would prefer to age in their own homes.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
› Verified 6 days ago
Ms. Martha E Montour, RN Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 580 Mohawk Dr, Boulder, CO 80303 Phone: 303-440-2690 | |
Chester J Dreiman, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2562 Briarwood Dr, Boulder, CO 80305 Phone: 303-501-2195 | |
Pamela G Ingram, MSN Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 580 Mohawk Dr, Boulder, CO 80303 Phone: 303-554-5164 | |
Bradley D Fanestil, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4801 Riverbend Rd Ste 120b, Boulder, CO 80301 Phone: 303-415-8615 Fax: 303-293-0628 | |
Dr. Joseph Randall Lutt, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1840 Folsom St Ste 105, Boulder, CO 80302 Phone: 720-494-4706 Fax: 720-494-4706 | |
Dr. Amy O Campbell, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2880 Folsom St Ste 100, Boulder, CO 80304 Phone: 303-327-7047 Fax: 303-443-7168 | |
Wael F. Garas, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5495 Arapahoe Ave Ste 100, Boulder, CO 80303 Phone: 303-415-4250 Fax: 303-440-9629 |